Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Labeling Format Differentiation Minimized By Rule Implementation Timeline

Executive Summary

FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products

You may also be interested in...



Labeling Rule Requires Sponsors To Start Safety Discussions With FDA Earlier

Sponsors will need to discuss safety updates to product labeling in the new format ahead of a submission to the agency in order to facilitate the prior approval necessary under the physician labeling rule

Labeling Rule Requires Sponsors To Start Safety Discussions With FDA Earlier

Sponsors will need to discuss safety updates to product labeling in the new format ahead of a submission to the agency in order to facilitate the prior approval necessary under the physician labeling rule

Merck Re-Enters Oncology With Zolinza Approval For Rare Skin Cancer

Merck's oncologic Zolinza will be available mid-October at a cost of $60 per capsule, the company said following vorinostat's Oct. 6 approval for a rare skin cancer.

Related Content

UsernamePublicRestriction

Register

PS046807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel